explore -WSS

explore

author：leisure time 2025-09-06 03:40:05 - browse：77284

Duchenne muscular dystrophy is a devastating disease and, until very recently, was one without much hope. When Hawken Miller was diagnosed at age 5, the physician told his parents to enjoy the time they had with him, as there wouldn’t be much. Over 20 years later, Miller is a journalist and content strategist for CureDuchenne, an organization started by his mother when he was diagnosed, and new treatment is on the horizon.

Last month, the FDA approved a new gene therapy from Sarepta Therapeutics that will provide hope for many patients and families. The new drug, however, has its limitations — it’s only approved for children age 4-5, for example. Miller joined the podcast to discuss how this drug may change lives, what more needs to happen, and what his personal experience has been living with Duchenne.

“For the older boys, we’re running up against the clock a little bit with what we’re able to do and what we’re not able to do,” Miller said. “And if we’re able to try anything that could possibly help, I think most people would like the opportunity to do that.”

The conversation is based off his recent First Opinion, “The FDA’s approval of a new gene therapy for Duchenne muscular dystrophy won’t help me — but it gives me hope.”

Be sure to sign up for the weekly “First Opinion Podcast” on Apple Podcasts, Stitcher, Google Play, or wherever you get your podcasts.

Previous article： After affirmative action ruling, medical educators look to 'holistic review'
Next article： FDA clears Verve to begin U.S. study of gene

WSS

STAT Summit: Meghan O’Rourke on making chronic illness visible

FDA clears Verve to begin U.S. study of gene

Amid AI frenzy, a top HHS official's quest to create safeguards

STAT Summit: Doctor v. ChatGPT showed AI's promise, blind spots

UCLA team creates talking throat patch for voice disorders

Roche acquires Telavant from Roivant, adding experimental IBD treatment

hotspot

explore

leisure time

Moonlake's readout produced a cash windfall. Risks remain

R.J. Reynolds sues to protect 'crisp' cigs from California flavor ban

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Readout Newsletter: AstraZeneca's CEO, Roivant's $5 billion deal

Novavax promises a turnaround & Lilly roils the obesity market

Readout Newsletter: AstraZeneca's CEO, Roivant's $5 billion deal

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Study on Amgen’s bispecific immunotherapy produces positive data

Alkermes shareholders re

Harvard's Jason Buenrostro wins MacArthur grant for genetics work

hotspot

Pushing for an NIH office for post

Amid AI frenzy, a top HHS official's quest to create safeguards

Harvard's Jason Buenrostro wins MacArthur grant for genetics work

STAT Summit: Ending the crisis of Black deaths in the U.S.

Boston's new lab space is opening empty

The future of Biogen: Pragmatism, ‘moonshots,’ and no Twinkies

focus

focus

leisure time

leisure time